Caribou Biosciences, Inc. (Nasdaq: CRBU), a prominent clinical-stage CRISPR genome-editing biopharmaceutical company, has announced a webcast scheduled for 8:00 AM ET on November 3, 2025. The session will focus on presenting new data from the ANTLER phase 1 clinical trial, which assesses vispacabtagene regedleucel (vispa-cel; previously known as CB-010), an allogeneic anti-CD19 CAR-T cell therapy for patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Additionally, the company will unveil the initial clinical data from the CaMMouflage phase 1 trial regarding CB-011, an allogeneic anti-BCMA CAR-T cell therapy targeting relapsed or refractory multiple myeloma (r/r MM).
During the webcast, Caribou will also outline its anticipated pivotal phase 3 trial design for vispa-cel, as well as the next steps for the ongoing clinical development of CB-011. Interested participants can access the live presentation through Caribou”s Events page on its website, and an archived version will be available for 30 days following the event.
Vispacabtagene regedleucel is noteworthy as it is reportedly the first allogeneic CAR-T cell therapy in clinical trials featuring a PD-1 knockout. This innovative genome-editing approach aims to enhance CAR-T cell efficacy by mitigating premature exhaustion of the cells. The FDA has awarded vispa-cel several designations, including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track for B-NHL. Further details on the ANTLER trial can be accessed at clinicaltrials.gov under the identifier NCT04637763.
CB-011, on the other hand, represents an allogeneic anti-BCMA CAR-T cell therapy currently being tested in patients with r/r MM in the CaMMouflage phase 1 trial. According to Caribou, CB-011 is pioneering as the first allogeneic CAR-T cell therapy designed to function by utilizing an immune cloaking strategy, which includes a B2M knockout and the introduction of a B2M-HLA-E fusion protein to reduce the likelihood of immune rejection. The FDA has also granted CB-011 Fast Track and Orphan Drug designations, with additional information available at clinicaltrials.gov under NCT05722418.
Caribou Biosciences, Inc. is committed to developing transformative therapies for patients suffering from severe diseases through its advanced genome-editing platform, which leverages Cas12a chRDNA technology for enhanced precision in creating cell therapies. The focus on vispacabtagene regedleucel (vispa-cel) and CB-011 reflects the company”s goal of providing accessible, off-the-shelf CAR-T cell therapies for patients with hematologic malignancies. For more updates, follow the company on social media at @CaribouBio or visit their website at www.cariboubio.com.
For inquiries, contact: Peggy Vorwald, PhD at [email protected] or [email protected].
